Speculation soars over Pfizer's interest in biotech
The buzz over Pfizer's biopharma ambitions continues with analyst George Grofik speculating about the possibilities of a Biogen Idec acquisition versus, say, Amgen or Wyeth. Biogen Idec's starting price is around $23 billion, while Amgen could fetch $62 billion, give or take a few billion. Grofik is looking for a few bite-sized acquisitions followed by a mid-sized buyout for Pfizer. But that doesn't leave the pharma giant looking any better to the analyst. Grofik still has the company stock on "hold."
- read the report from the Wall Street Journal (sub. req.)
ALSO: It's official: Pfizer is killing off Exubera. Report
Related Articles:
Who should Pfizer buy? Report
Pfizer hires new R&D chief, launches biotech center. Report
Pfizer's future rests with biotech. Report
Biogen Idec in play after Icahn makes his move. Report
Read more on: Pfizer | Biogen Idec | Amgen | Wyeth
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage
